Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Biodistribution of 18F-OP-801 in Neurodegenerative Diseases
NCT05395624Phase 2Recruiting
- Start
- Feb 2023
- Primary completion
- Jan 2026
- Modality
- Polymer-based Nanoparticles
- Countries
- 1
01
Overview
Phase 2, open-label trial of [18F]OP-801 in amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), multiple sclerosis (MS) and 1 more (5 arms). Primary endpoint: Treatment Emergent Adverse Events. Started Feb 2023; status: recruiting.
02
Drugs
[18F]OP-801
03
Conditions
amyotrophic lateral sclerosis (ALS)Alzheimer's disease (AD)multiple sclerosis (MS)Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05395624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05395624.